ASH 2023 | Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL
Fabio Guolo
• 10 Dec 2023
Fabio Guolo, MD, University of Genoa, Genoa, Italy, introduces a study evaluating the efficacy of PD1 blockade with nivolumab or pembrolizumab alongside autologous lymphocyte reinfusion following chemotherapy and autologous stem cell transplantation (autoSCT) in patients with relapsed/refractory Hodgkin lymphoma (HL). The study found a complete response (CR) rate of 100%, with the underlying biological mechanism involving the expansion of natural killer (NK) cells. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
